Most Read Articles
2 days ago
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
Pearl Toh, 6 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
4 days ago
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.
3 days ago
Middle-aged Caucasian men who are dissatisfied with their marriage are at higher risk of sudden cardiac death regardless of other cardiovascular risk factors, a new study reports.

Risk factors for nonalcoholic steatohepatitis, advanced fibrosis in Asian patients

Jairia Dela Cruz
10 Feb 2018

In Asian patients with nonalcoholic fatty liver disease (NAFLD), more severe liver disease is associated with factors such as older age, obesity, diabetes, dyslipidaemia, higher alanine transaminase (ALT) and aspartate transaminase (AST) levels, and lower platelet count, according to a team of investigators.

Nonalcoholic steatohepatitis (NASH) and advanced fibrosis can be suspected or ruled out based on factors identified in this study, they added. This is of paramount importance as the current practice of diagnosing more severe liver disease is based on histopathological examination of a liver biopsy specimen, with the liver biopsy procedure being invasive and should not be applied to all NAFLD patients.

The investigators from eight Asian countries—including Singapore, Hong Kong, Malaysia, Japan and Korea—had used the Gut and Obesity Asia (GO ASIA) Workgroup as a platform to share their data on biopsy-proven NAFLD patients, determine factors associated with NASH and advanced fibrosis, and look into the medical management of NAFLD in the region.

A total of 1,008 patients were included (62.9 percent had NASH; 17.2 percent had advanced fibrosis), among whom 483 were assigned into a training cohort (mean age 45.4 years; 59.2 percent male) and 525 into a validation cohort (mean age 48.5 years; 53.9 percent).

In the training cohort, factors including body mass index ≥30 kg/m2 (odds ratio [OR], 3.506; p<0.001), diabetes mellitus (OR, 1.581; p=0.038), dyslipidaemia (OR, 1.674; p=0.037), ALT ≥88 U/L (OR, 1.856; p=0.041) and AST ≥38 U/L (OR, 1.805; p=0.025) emerged as independent predictors of NASH. Those associated with advanced fibrosis included age ≥55 years old (OR, 4.693; p<0.001), diabetes mellitus (OR, 2.046; p=0.015) and platelet count <150 9 109 /L (OR, 2.572; p=0.034). [Aliment Pharmacol Ther 2018;doi:10.1111/apt.14506]

The aforementioned factors constituted the Asia-Pacific NASH and NAFLD advanced fibrosis risk scores. A high score yielded a positive predictive value of 80–83 percent for NASH and a low score yielded a negative predictive value of 95–96 percent for advanced fibrosis in the training and validation cohorts.

In terms of NAFLD management, the current data indicated limited utilization of structured lifestyle programme and treatment with vitamin E or pioglitazone. This is despite the fact that the cohort involved biopsy-proven NAFLD patients, with majority of patients having NASH.

“It is important to note [though] that the treatment strategies in different countries are influenced by the healthcare structure and evidence. For example, reimbursement may range from almost fully supported by the government (eg, Hong Kong), copayment system (eg, Singapore), insurance-driven (eg, Korea) to limited support (eg, the Philippines),” the investigators said.

“Unfortunately, short of lifestyle interventions and isolated drug trials, Asian centres have not been much involved in drug development for NASH. The lack of local data may also affect the choice of therapies,” they added.

To address such lack, the investigators suggested that clinicians and researchers with interest in NAFLD in the region use the GO ASIA Workgroup as a platform to consolidate and expand the current understanding of the disease through combining and sharing of data from previous, current and future work.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
Pearl Toh, 6 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
4 days ago
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.
3 days ago
Middle-aged Caucasian men who are dissatisfied with their marriage are at higher risk of sudden cardiac death regardless of other cardiovascular risk factors, a new study reports.